- A strong and growing portfolio of IP capturing credible, internally validated technology
- World-class in-house expertise with pioneers in graphene and nanotechnology leading Archer’s projects
- Access to more than $300 million of state-of-art R&D infrastructure to build and test technology products
- A diverse advanced materials inventory for rapid device prototyping and integration
What does Archer do?
The company has a strong intellectual property, broad scope mineral tenements, world-class-in-house expertise, a diverse advanced materials inventory and access to more than $300 million of research and development (R&D) infrastructure.
Archer provides shareholders with exposure to financial returns from innovative technologies and the materials that underpin them by:
- Developing its advanced materials business in the key areas of quantum technology, human health and reliable energy;
- Effectively exploring mineral exploration projects; and
- Identifying opportunities to acquire new value add projects and to realise value through the sale of existing needs.
What does Archer own?
Archer’s graphene-based biosensor technology is unique and has the potential to positively disrupt the global MedTech industry.
There are very few materials in existence that can be used to perform biosensing rapidly and accurately for human health diagnostics.
The company is developing a graphene-based biosensor device that, if successful, will allow for rapid, highly sensitive, portable testing for in-vitro diagnostics.
The global biosensor market revenue is expected to grow to US$27 billion by 2022 with a global need for healthcare to become cheaper, efficient and more accessible.
Key driving factors of growth are aging populations in North America, Asia and Europe. Europe is the largest contributor in the printed sensor market.
Archer is also developing the intellectual property (IP) associated with a potential solution to printable graphene biosensors capable of complex detection of disease, which could then be used to generate revenue from licencing the IP to companies in the biotech industry.
The company believes it has something that no one else has - highly processable graphene materials that allow for selective hierarchal chemistry to the single molecule level with the potential to solve selectivity and detection challenges in biosensing.
What are Archer’s next steps?
The roadmap to commercialising Archer’s graphene-based biosensor includes:
- Successfully prosecute patent applications in Australia and around the world in order to provide the commercial freedom to operate in these markets;
- De-risk the technology by progressively building a functioning biosensor; and
- Establish commercial partnerships with highly resourced organisations in the biotechnology industry.
The company has provisionally patented IP related to the graphene-based biosensor technology and intends to lodge a Patent Cooperation Treaty (PCT) by February 15, 2020.
Its focus is on manufacturing a commercially viable graphene-based biosensory technology as well as the registration of a full patent application protecting the underlying materials technology IP.
This will allow Archer to decide which countries to have patent protection in and allow for international protection.
A PCT application will go through an examination process according to a set of standards accepted by all the 151 countries which are signatories to the treaty.